Login to Your Account

Pharma: Other News To Note

Thursday, September 6, 2012
• Pfizer Inc., of New York, said the FDA approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML). The drug is intended for patients with chronic, accelerated or blast phase Philadelphia chromosome-positive CML who are resistant to or who cannot tolerate other therapies, including Gleevec (imatinib, Novartis AG).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription